Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Trevi Therapeutics resumes patient screening for Phase 2 trial of Haduvio » 08:20
10/21/20
10/21
08:20
10/21/20
08:20
TRVI

Trevi Therapeutics

$3.44 /

-0.005 (-0.15%)

Trevi Therapeutics…

Trevi Therapeutics announced updates to their ongoing clinical trials of Haduvio. Patient screening has resumed for the Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis, a trial that was paused due to IPF patients being an at-risk population for COVID-19. In addition, the Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis, randomized its 180th subject, officially reaching 50% enrollment. Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis: The Phase 2 clinical trial is a randomized, double-blind, placebo controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, tolerability and dosing of nalbuphine ER for chronic cough in patients with IPF that is being conducted in the United Kingdom. The study is designed to enroll approximately 60 subjects with a goal to have 44 study completers. The primary endpoint for the study is the mean percent change in daytime cough frequency as measured by a cough monitor. The study will also examine various secondary endpoints. The amended protocol was recently approved by the Medicines and Healthcare products Regulatory Agency of the UK and patient screening has restarted at certain sites in the UK. Additionally, Trevi is analyzing the possible addition of study sites in Germany to potentially accelerate enrollment and mitigate the COVID-related risks inherent to recruitment from a single-country. Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis: During October, the PRISM trial randomized its 180th subject into the study, reaching 50% enrollment of the expanded trial size following the sample size re-estimation completed in July. We expect to complete enrollment in the PRISM trial in the third quarter of 2021 and report top-line data in the fourth quarter of 2021.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$3.44 /

-0.005 (-0.15%)

TRVI Trevi Therapeutics
$3.44 /

-0.005 (-0.15%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
TRVI Trevi Therapeutics
$3.44 /

-0.005 (-0.15%)

Conference/Events
Trevi Therapeutics management to meet virtually with Needham » 04:55
10/21/20
10/21
04:55
10/21/20
04:55
TRVI

Trevi Therapeutics

$3.44 /

-0.005 (-0.15%)

Virtual Meeting to be…

Virtual Meeting to be held on October 21 hosted by Needham.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$3.44 /

-0.005 (-0.15%)

TRVI Trevi Therapeutics
$3.44 /

-0.005 (-0.15%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
TRVI Trevi Therapeutics
$3.44 /

-0.005 (-0.15%)

Conference/Events
Trevi Therapeutics management to meet virtually with Needham » 11:29
10/19/20
10/19
11:29
10/19/20
11:29
TRVI

Trevi Therapeutics

$3.45 /

-0.01 (-0.29%)

Virtual Meeting to be…

Virtual Meeting to be held on October 21 hosted by Needham.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$3.45 /

-0.01 (-0.29%)

TRVI Trevi Therapeutics
$3.45 /

-0.01 (-0.29%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
TRVI Trevi Therapeutics
$3.45 /

-0.01 (-0.29%)

Over a quarter ago
Earnings
Trevi Therapeutics reports Q2 net loss $7.38M » 16:17
08/13/20
08/13
16:17
08/13/20
16:17
TRVI

Trevi Therapeutics

$5.66 /

-0.93 (-14.11%)

As of June 30, the…

As of June 30, the company had total cash and cash equivalents of $44.2M, compared to $57.3M as of December 31, 2019. "We are pleased with how the Trevi team was able to manage the continued execution of the PRISM trial in the face of the COVID-19 pandemic restrictions. The Company announced the positive outcome of the sample size re-estimation analysis and continued to activate clinical sites virtually," said Jennifer L. Good, President and CEO of Trevi Therapeutics. "Once the screening and enrollment restrictions were lifted in the PRISM trial, we were able to rapidly restart screening and enrollment in most of our sites. We now have approximately 80% of our sites screening patients and have had our strongest two months of enrollment thus far in the trial. In addition, we are pleased to announce the execution of a non-dilutive $14 million term loan which we expect will extend our cash runway into the first half of 2022, past the anticipated top-line results from the PRISM trial which are expected in the fourth quarter of 2021."

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.66 /

-0.93 (-14.11%)

TRVI Trevi Therapeutics
$5.66 /

-0.93 (-14.11%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
TRVI Trevi Therapeutics
$5.66 /

-0.93 (-14.11%)

Recommendations
Trevi Therapeutics price target lowered to $10 from $14 at Stifel » 11:50
07/13/20
07/13
11:50
07/13/20
11:50
TRVI

Trevi Therapeutics

$5.65 /

-0.17 (-2.92%)

Stifel analyst Annabel…

Stifel analyst Annabel Samimy lowered the firm's price target on Trevi Therapeutics to $10 from $14 and keeps a Buy rating on the shares after the company announced the completion of the pre-specified sample size re-estimation analysis for the ongoing PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis. The independent Data Monitoring Committee has recommended that PRISM continue, which suggests activity, but the 50% suggested increase in patients is large relative to re-estimations of other clinical trials, said Samimy. The main impact of the sample size re-estimation about a one year delay to PRISM timelines and she has shifted her estimates out accordingly, the analyst tells investors.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.65 /

-0.17 (-2.92%)

TRVI Trevi Therapeutics
$5.65 /

-0.17 (-2.92%)

Hot Stocks
Trevi completes pre-specified SSRE analysis for PRISM Phase 2b/3 trial » 07:42
07/13/20
07/13
07:42
07/13/20
07:42
TRVI

Trevi Therapeutics

$5.82 /

+0.23 (+4.11%)

Trevi Therapeutics…

Trevi Therapeutics announced the completion of the pre-specified sample size re-estimation analysis for the ongoing PRISM Phase 2b/3 trial of Haduvio for severe pruritus in patients with prurigo nodularis. Based on the SSRE analysis the independent Data Monitoring Committee recommended that the PRISM trial should continue and that the trial size should increase from an initial enrollment target of 240 to 360 subjects which maintains the statistical power for the primary endpoint. The DMC's recommendation was based on a pre-specified interim conditional power assessment conducted after approximately 45% of the initial targeted number of patients were evaluable for the primary endpoint of the trial. Based on the DMC's recommendation, the Company plans to increase the size of the trial to 360 subjects. "Severe pruritus in prurigo nodularis is a very serious and difficult-to-treat condition. We are pleased with the re-estimation results midway through the trial which inform the sample size and further reinforces our view that Haduvio may be an effective treatment option for patients with PN," said Jennifer L. Good, President and CEO of Trevi Therapeutics. "Enrollment in the PRISM trial has been picking up nicely since the removal of most COVID-19 screening and enrollment restrictions. We have increased the number of active sites to more than 60 globally and approximately 140 subjects have enrolled in the study. Based on the increased sample size, and considering COVID-19 related restrictions, we expect to complete enrollment in the third quarter of 2021 and report top-line data in the fourth quarter of 2021."

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.82 /

+0.23 (+4.11%)

TRVI Trevi Therapeutics
$5.82 /

+0.23 (+4.11%)

Syndicate
Trevi Therapeutics files $150M mixed securities shelf  17:06
06/26/20
06/26
17:06
06/26/20
17:06
TRVI

Trevi Therapeutics

$5.95 /

+0.21 (+3.66%)

 
ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.95 /

+0.21 (+3.66%)

TRVI Trevi Therapeutics
$5.95 /

+0.21 (+3.66%)

Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

Frequency Therapeutics

$22.68 /

-0.47 (-2.03%)

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley Securities
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

Earnings
Trevi Therapeutics reports Q1 net loss of $8.5M versus $4.8M last year » 17:04
05/07/20
05/07
17:04
05/07/20
17:04
TRVI

Trevi Therapeutics

$2.69 /

+0.04 (+1.51%)

Cash position: As of…

Cash position: As of March 31, 2020, Trevi reported total cash and cash equivalents of $52.6 million, compared to $57.3 million as of December 31, 2019. Trevi believes this cash position will be sufficient to fund operations into the fourth quarter of 2021.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.69 /

+0.04 (+1.51%)

06/03/19 Needham
Trevi Therapeutics initiated with a Buy at Needham
06/03/19 BMO Capital
Trevi Therapeutics initiated with an Outperform at BMO Capital
06/03/19 SVB Leerink
Trevi Therapeutics initiated with an Outperform at SVB Leerink
06/03/19 Stifel
Trevi Therapeutics initiated with a Buy at Stifel
Hot Stocks
Trevi Therapeutics expects cash, cash equivalents to fund operations into 3Q21 » 08:10
03/16/20
03/16
08:10
03/16/20
08:10
TRVI

Trevi Therapeutics

$2.50 /

-0.85 (-25.37%)

As of December 31, 2019,…

As of December 31, 2019, total cash and cash equivalents were $57.3M compared to $7.2M as of December 31, 2018. Trevi believes this cash position will be sufficient to fund operations into the third quarter of 2021.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.50 /

-0.85 (-25.37%)

06/03/19 Needham
Trevi Therapeutics initiated with a Buy at Needham
06/03/19 BMO Capital
Trevi Therapeutics initiated with an Outperform at BMO Capital
06/03/19 SVB Leerink
Trevi Therapeutics initiated with an Outperform at SVB Leerink
06/03/19 Stifel
Trevi Therapeutics initiated with a Buy at Stifel

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.